No statistically significant therapy-by-subgroup interactions (for BMI, age at entry, menopausal status, use of HRT, baseline breast density, and smoking status)
No statistically significant therapy-by-subgroup interactions (for BMI and age at entry)
Exemestane
−0.17 (95% CI from −4.34 to 4.00)
0.37
Placebo
−2.93 (95% CI from −8.70 to 2.85)
ccHRT: continuous-combined hormone therapy that consisted of conjugated equine estrogen 0.625 mg/day plus medroxyprogesterone acetate 2.5 mg/day. NMTA: no multivariable analysis of interaction with treatment effect available. ΔMRIV = change in breast MRI volume. 1The mean density within the placebo group and both raloxifene groups decreased statistically significantly from baseline ( for each group), while the mean density in the ERT (estrogen replacement therapy) group increased but not statistically significantly. 2E2-HER: computer-based (E2-specific) heterogeneity examination of radiographs. 3None of the patients in either treatment group demonstrated a decrease in breast density; using area % measurement: no significant increase from baseline. NA: not available. 4Only in one patient did the BI-RADS classification of 2 change to 3 after 12 months of therapy. 5HRT: hormonal replacement therapy. 6IPI: computerized calculation of integrated pixel intensity.